The effects of Berberis vulgaris L. and Berberis aristata L. in metabolic syndrome patients: a systematic and meta-analysis study

References

• Awasthi, H., et al., 2015. Effects of a standardized ayurvedic formulation on diabetes control in newly diagnosed type-2 diabetics; a randomized active controlled clinical study. Complementary therapies in medicine, 23 (4), 555–561.
   PubMed Web of Science ®Google Scholar
• Banos, G., Pérez-Torres, I., and El Hafidi, M., 2008. Medicinal agents in the metabolic syndrome. Cardiovascular & hematological agents in medicinal chemistry (Formerly Current medicinal chemistry-cardiovascular & hematological agents), 6 (4), 237–252.
   PubMedGoogle Scholar
• Bianchi, C., et al., 2007. Treating the metabolic syndrome. Expert review of cardiovascular therapy, 5 (3), 491–506.
   PubMedGoogle Scholar
• Chakrabarti, R., et al., 2011. Dipeptidyl peptidase-IV inhibitory activity of Berberis aristata. Journal of natural products, 4, 158–163.
   Google Scholar
• Cicero, A.F.G., et al., 2017. Nutraceutical effects on glucose and lipid metabolism in patients with impaired fasting glucose: a pilot, double-blind, placebo-controlled, randomized clinical trial on a combined product. High blood pressure & cardiovascular prevention: the official journal of the Italian society of hypertension, 24 (3), 283–288.
   PubMed Web of Science ®Google Scholar
• Day, C., 2007. Metabolic syndrome, or what you will: definitions and epidemiology. Diabetes & vascular disease research, 4 (1), 32–38.
   PubMedGoogle Scholar
• Derosa, G., et al., 2013a. Berberis aristata/Silybum marianum fixed combination on lipid profile and insulin secretion in dyslipidemic patients. Expert opinion on biological therapy, 13 (11), 1495–1506.
   PubMed Web of Science ®Google Scholar
• Derosa, G., et al., 2013b. Effects of Berberis aristata/Silybum marianum association on metabolic parameters and adipocytokines in overweight dyslipidemic patients. Journal of biological regulators and homeostatic agents, 27 (3), 717–728.
   PubMed Web of Science ®Google Scholar
• Derosa, G., et al., 2015a. Berberis aristata combined with Silybum marianum on lipid profile in patients not tolerating statins at high doses. Atherosclerosis, 239 (1), 87–92.
   PubMed Web of Science ®Google Scholar
• Derosa, G., et al., 2015b. Berberis aristata/Silybum marianum fixed combination (Berberol®) effects on lipid profile in dyslipidemic patients intolerant to statins at high dosages: a randomized, placebo-controlled, clinical trial. Phytomedicine: international journal of phytotherapy and phytopharmacology, 22 (2), 231–237.
   PubMed Web of Science ®Google Scholar
• Derosa, G., D’Angelo, A., and Maffioli, P., 2016. The role of a fixed Berberis aristata/Silybum marianum combination in the treatment of type 1 diabetes mellitus. Clinical nutrition (Edinburgh, Scotland), 35 (5), 1091–1095.
   PubMed Web of Science ®Google Scholar
• Dong, H., et al., 2012. Berberine in the treatment of type 2 diabetes mellitus: a systemic review and meta-analysis. Evidence-based complementary and alternative medicine: Ecam, 2012, 591654.
   PubMed Web of Science ®Google Scholar
• Farkhondeh, T., and Samarghandian, S., 2016. Antidotal effects of curcumin against agents-induced cardiovascular toxicity. Cardiovascular & haematological disorders-drug targets, 16 (1), 30–37.
   Google Scholar
• Farvid, M.S., et al., 2004. The impact of vitamin and/or mineral supplementation on lipid profiles in type 2 diabetes. Diabetes research and clinical practice, 65 (1), 21–28.
   PubMed Web of Science ®Google Scholar
• Gogia, A., and Agarwal, P.K., 2006. Metabolic syndrome. Indian journal of medical sciences, 60 (2), 72–81.
   PubMedGoogle Scholar
• Guarino, G., et al., 2017. Bioimpedance analysis, metabolic effects and safety of the association Berberis aristata/Bilybum marianum: a 52-week double-blind, placebo-controlled study in obese patients with type 2 diabetes. Journal of biological regulators and homeostatic agents, 31 (2), 495–502.
   PubMed Web of Science ®Google Scholar
• Heidarian, E., et al., 2014. Metabolic effects of berberine on liver phosphatidate phosphohydrolase in rats fed on high lipogenic diet: an additional mechanism for the hypolipidemic effects of berberine. Asian Pacific journal of tropical biomedicine, 4, S429–S435.
   PubMedGoogle Scholar
• Imanshahidi, M., and Hosseinzadeh, H., 2008. Pharmacological and therapeutic effects of Berberis vulgaris and its active constituent, berberine. Phytotherapy research: PTR, 22 (8), 999–1012.
   PubMed Web of Science ®Google Scholar
• Kashkooli, R.I., et al., 2015. The effect of Berberis vulgaris extract on transaminase activities in non-alcoholic fatty liver disease. Hepatitis monthly, 15 (2). doi:10.5812/hepatmon.25067
   Web of Science ®Google Scholar
• Kasper, D. L., et al., 2001. Harrison’s principles of internal medicine (Vol. 1). E. Braunwald (Ed.). New York: McGraw-Hill.
   Google Scholar
• Kong, W., et al., 2004. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nature medicine, 10 (12), 1344–1351.
   PubMed Web of Science ®Google Scholar
• Lazavi, F., et al., 2018. The barberry juice effects on metabolic factors and oxidative stress in patients with type 2 diabetes: a randomized clinical trial. Complementary therapies in clinical practice, 31, 170–174.
   PubMed Web of Science ®Google Scholar
• Moazezi, Z., and Qujeq, D., 2014. Berberis fruit extract and biochemical parameters in patients with type II diabetes. Jundishapur journal of natural pharmaceutical products, 9 (2). doi:10.17795/jjnpp-13490
   PubMedGoogle Scholar
• Paolisso, G., et al., 1996. Does free fatty acid infusion impair insulin action also through an increase in oxidative stress? The journal of clinical endocrinology & metabolism, 81 (12), 4244–4248.
   PubMed Web of Science ®Google Scholar
• Rashidi, H., et al., 2018. The effects of active ingredients of barberry root (berberine) on glycemic control and insulin resistance in type 2 diabetic patients. Jundishapur journal of natural pharmaceutical products, 13 (1). doi:10.5812/jjnpp.64180
   Google Scholar
• Scheen, A., 2004. Management of the metabolic syndrome. Minerva endocrinologica, 29 (2), 31–45.
   PubMedGoogle Scholar
• Sharma, R.K., et al., 2017. Evaluation of hypolipidemic effect of stem part of Berberis aristata in type 2 diabetes mellitus patients as add on therapy. National journal of physiology, pharmacy and pharmacology, 7 (11), 1159–1169.
   Google Scholar
• Shidfar, F., et al., 2012. The effects of Berberis vulgaris fruit extract on serum lipoproteins, apoB, apoA-I, homocysteine, glycemic control and total antioxidant capacity in type 2 diabetic patients. Iranian journal of pharmaceutical research: IJPR, 11 (2), 643–652.
   PubMed Web of Science ®Google Scholar
• Singh, J., and Kakkar, P., 2009. Antihyperglycemic and antioxidant effect of Berberis aristata root extract and its role in regulating carbohydrate metabolism in diabetic rats. Journal of ethnopharmacology, 123 (1), 22–26.
   PubMed Web of Science ®Google Scholar
• Sukandar, E.Y., et al., 2010. Clinical study of turmeric (Curcuma longa L.) and garlic (Allium sativum L.) extracts as antihyperglycemic and antihyperlipidemic agent in type-2 diabetes-dyslipidemia patients. International journal of pharmacology, 6 (4), 456–463.
   Web of Science ®Google Scholar
• Tahmasebi, L., et al., 2019. Randomised clinical trial of Berberis vulgaris root extract on glycemic and lipid parameters in type 2 diabetes mellitus patients. European journal of integrative medicine, 32, 100998.
   Web of Science ®Google Scholar